Cargando…

Alpha-synuclein and tau: teammates in neurodegeneration?

The accumulation of α-synuclein aggregates is the hallmark of Parkinson’s disease, and more generally of synucleinopathies. The accumulation of tau aggregates however is classically found in the brains of patients with dementia, and this type of neuropathological feature specifically defines the tau...

Descripción completa

Detalles Bibliográficos
Autores principales: Moussaud, Simon, Jones, Daryl R, Moussaud-Lamodière, Elisabeth L, Delenclos, Marion, Ross, Owen A, McLean, Pamela J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230508/
https://www.ncbi.nlm.nih.gov/pubmed/25352339
http://dx.doi.org/10.1186/1750-1326-9-43
_version_ 1782344280970362880
author Moussaud, Simon
Jones, Daryl R
Moussaud-Lamodière, Elisabeth L
Delenclos, Marion
Ross, Owen A
McLean, Pamela J
author_facet Moussaud, Simon
Jones, Daryl R
Moussaud-Lamodière, Elisabeth L
Delenclos, Marion
Ross, Owen A
McLean, Pamela J
author_sort Moussaud, Simon
collection PubMed
description The accumulation of α-synuclein aggregates is the hallmark of Parkinson’s disease, and more generally of synucleinopathies. The accumulation of tau aggregates however is classically found in the brains of patients with dementia, and this type of neuropathological feature specifically defines the tauopathies. Nevertheless, in numerous cases α-synuclein positive inclusions are also described in tauopathies and vice versa, suggesting a co-existence or crosstalk of these proteinopathies. Interestingly, α-synuclein and tau share striking common characteristics suggesting that they may work in concord. Tau and α-synuclein are both partially unfolded proteins that can form toxic oligomers and abnormal intracellular aggregates under pathological conditions. Furthermore, mutations in either are responsible for severe dominant familial neurodegeneration. Moreover, tau and α-synuclein appear to promote the fibrillization and solubility of each other in vitro and in vivo. This suggests that interactions between tau and α-synuclein form a deleterious feed-forward loop essential for the development and spreading of neurodegeneration. Here, we review the recent literature with respect to elucidating the possible links between α-synuclein and tau.
format Online
Article
Text
id pubmed-4230508
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42305082014-11-14 Alpha-synuclein and tau: teammates in neurodegeneration? Moussaud, Simon Jones, Daryl R Moussaud-Lamodière, Elisabeth L Delenclos, Marion Ross, Owen A McLean, Pamela J Mol Neurodegener Review The accumulation of α-synuclein aggregates is the hallmark of Parkinson’s disease, and more generally of synucleinopathies. The accumulation of tau aggregates however is classically found in the brains of patients with dementia, and this type of neuropathological feature specifically defines the tauopathies. Nevertheless, in numerous cases α-synuclein positive inclusions are also described in tauopathies and vice versa, suggesting a co-existence or crosstalk of these proteinopathies. Interestingly, α-synuclein and tau share striking common characteristics suggesting that they may work in concord. Tau and α-synuclein are both partially unfolded proteins that can form toxic oligomers and abnormal intracellular aggregates under pathological conditions. Furthermore, mutations in either are responsible for severe dominant familial neurodegeneration. Moreover, tau and α-synuclein appear to promote the fibrillization and solubility of each other in vitro and in vivo. This suggests that interactions between tau and α-synuclein form a deleterious feed-forward loop essential for the development and spreading of neurodegeneration. Here, we review the recent literature with respect to elucidating the possible links between α-synuclein and tau. BioMed Central 2014-10-29 /pmc/articles/PMC4230508/ /pubmed/25352339 http://dx.doi.org/10.1186/1750-1326-9-43 Text en © Moussaud et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Moussaud, Simon
Jones, Daryl R
Moussaud-Lamodière, Elisabeth L
Delenclos, Marion
Ross, Owen A
McLean, Pamela J
Alpha-synuclein and tau: teammates in neurodegeneration?
title Alpha-synuclein and tau: teammates in neurodegeneration?
title_full Alpha-synuclein and tau: teammates in neurodegeneration?
title_fullStr Alpha-synuclein and tau: teammates in neurodegeneration?
title_full_unstemmed Alpha-synuclein and tau: teammates in neurodegeneration?
title_short Alpha-synuclein and tau: teammates in neurodegeneration?
title_sort alpha-synuclein and tau: teammates in neurodegeneration?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230508/
https://www.ncbi.nlm.nih.gov/pubmed/25352339
http://dx.doi.org/10.1186/1750-1326-9-43
work_keys_str_mv AT moussaudsimon alphasynucleinandtauteammatesinneurodegeneration
AT jonesdarylr alphasynucleinandtauteammatesinneurodegeneration
AT moussaudlamodiereelisabethl alphasynucleinandtauteammatesinneurodegeneration
AT delenclosmarion alphasynucleinandtauteammatesinneurodegeneration
AT rossowena alphasynucleinandtauteammatesinneurodegeneration
AT mcleanpamelaj alphasynucleinandtauteammatesinneurodegeneration